IDEAYA Biosciences, Inc. reported a significant increase in collaboration revenue for the year ended December 31, 2025, reaching $218.7 million compared to $7.0 million in the previous year. This surge is attributed to the exclusive license agreement with Servier for darovasertib, a key product candidate. Despite the revenue increase, the company experienced a net loss of $113.7 million, a decrease from the $274.5 million net loss in 2024. This improvement is primarily due to the recognition of revenue from the Servier agreement, offsetting the substantial operating expenses associated with ongoing research and development activities.
The company's operating expenses totaled $378.0 million in 2025, up from $334.0 million in 2024. Research and development expenses accounted for the majority of this, increasing to $314.7 million from $294.7 million, driven by the advancement of product candidates through preclinical and clinical studies. General and administrative expenses also rose significantly, reaching $63.3 million compared to $39.3 million in the prior year, reflecting increased personnel costs and professional fees related to company growth and public company compliance. Interest income and other income, net, decreased to $45.6 million from $52.5 million, primarily due to lower interest rates.
IDEAYA continued to strategically advance its pipeline, with key developments including the completion of enrollment in the OptimUM-02 Phase 2/3 trial for darovasertib and the initiation of a Phase 3 trial in the neoadjuvant setting. The company also received IND clearance for IDE034 and IDE574, paving the way for Phase 1 trials. A $2.0 million milestone payment was made to Hengrui Pharma upon the initiation of the first Phase 1 clinical trial for IDE849. GSK notified IDEAYA of its intention to terminate the Collaboration, Option and License Agreement, dated June 15, 2020, which will be effective March 9, 2026.
As of December 31, 2025, IDEAYA's cash, cash equivalents, and marketable securities totaled $1.05 billion. The company believes these funds will be sufficient to support planned operations for at least the next 12 months. During 2025, IDEAYA sold 984,000 shares of common stock for net proceeds of $25.0 million through an at-the-market offering. The company is focused on advancing its precision medicine oncology therapies, leveraging strategic collaborations, and maintaining a strong financial position to support its clinical development programs.
About IDEAYA Biosciences, Inc.
Ideaya Biosciences is a precision medicine oncology company developing targeted small molecule therapeutics and companion diagnostics for genetically defined cancers. Its pipeline includes clinical-stage candidates targeting PKC, MAT2A, DLL3, Pol Theta Helicase, PARG, and KAT6/7, with a focus on biomarker-driven patient populations. The company collaborates with leading pharma firms, owns extensive proprietary platforms, and aims to address unmet needs in cancer treatment through innovative, targeted therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.